Amgen's Enbrel Patents to Be Upheld Through 2029

Americans with psoriasis and rheumatoid arthritis will have to wait much longer for low-priced copycat versions of their weekly Enbrel injections. Amgen (NASDAQ: AMGN) won an appeals court ruling on Wednesday that will block the sale of Erlelzi from Novartis (NYSE: NVS) and all other biosimilar versions of Enbrel until 2029 at the earliest.